PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Kure Cells, INC • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to tame aggressive lymphoma in frail patients
Disease control Not yet recruitingThis early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental immune cell cocktail targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cell therapy aims to wipe out lingering lymphoma before it returns
Disease control Not yet recruitingThis early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for lymphoma: immune booster plus chemotherapy trial launches
Disease control Not yet recruitingThis Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New 'Off-the-Shelf' cell therapy takes aim at tough lymphoma
Disease control Not yet recruitingThis early-phase study tests a new treatment called QH103 for adults with B-cell lymphoma that has come back or not responded to standard therapy. QH103 uses specially engineered immune cells (CAR-γδT cells) from healthy donors to target and kill cancer cells. The main goals are …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: The Second Affiliated Hospital of Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New combo therapy aims to beat tough lymphoma
Disease control Not yet recruitingThis study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental CAR-T therapy takes aim at tough blood cancers
Disease control Not yet recruitingThis early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will a…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC